Shandong Sinobioway Biomedicine Co Ltd Total Liabilities
Shandong Sinobioway Biomedicine Co Ltd total liabilities. Based on the latest financial reports, Shandong Sinobioway Biomedicine Co Ltd (002581) has total liabilities worth CN¥176.06 Million CNY (≈ $25.76 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Shandong Sinobioway Biomedicine Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shandong Sinobioway Biomedicine Co Ltd (2007–2025)
Total liabilities of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2025. This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 002581 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Shandong Sinobioway Biomedicine Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Sinobioway Biomedicine Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥277.60 Million |
|
Attica Holdings S.A.
AT:ATTICA
|
Greece | €855.40 Million |
|
Wuxi Smart Auto-control Engineering Co Ltd
SHE:002877
|
China | CN¥1.20 Billion |
|
Shenzhen Keanda Electronic Techno
SHE:002972
|
China | CN¥206.27 Million |
|
InPlay Oil Corp
TO:IPO
|
Canada | CA$795.00 Million |
|
First Carolina Financial Services, Inc.
NYSE:FCBM
|
USA | $2.97 Billion |
|
LF Corp
KO:093050
|
Korea | ₩1.30 Trillion |
|
Zhejiang Jinfei Kaida Wheel Co Ltd
SHE:002863
|
China | CN¥6.53 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Shandong Sinobioway Biomedicine Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002581 total assets.
Liquidity & Leverage Metrics
Shandong Sinobioway Biomedicine Co Ltd Total Liabilities Ratios Explained
Shandong Sinobioway Biomedicine Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Sinobioway Biomedicine Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Sinobioway Biomedicine Co Ltd (2007–2025)
The table below shows the annual total liabilities of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥222.00 Million ≈ $32.48 Million |
+27.87% |
| 2024-12-31 | CN¥173.61 Million ≈ $25.40 Million |
+6.24% |
| 2023-12-31 | CN¥163.41 Million ≈ $23.91 Million |
-58.04% |
| 2022-12-31 | CN¥389.46 Million ≈ $56.99 Million |
+35.82% |
| 2021-12-31 | CN¥286.76 Million ≈ $41.96 Million |
+12.75% |
| 2020-12-31 | CN¥254.33 Million ≈ $37.22 Million |
-75.19% |
| 2019-12-31 | CN¥1.03 Billion ≈ $150.01 Million |
-30.42% |
| 2018-12-31 | CN¥1.47 Billion ≈ $215.60 Million |
+36.57% |
| 2017-12-31 | CN¥1.08 Billion ≈ $157.87 Million |
+573.61% |
| 2016-12-31 | CN¥160.16 Million ≈ $23.44 Million |
-41.10% |
| 2015-12-31 | CN¥271.92 Million ≈ $39.79 Million |
+1254.00% |
| 2014-12-31 | CN¥20.08 Million ≈ $2.94 Million |
-43.42% |
| 2013-12-31 | CN¥35.49 Million ≈ $5.19 Million |
+44.19% |
| 2012-12-31 | CN¥24.62 Million ≈ $3.60 Million |
+37.41% |
| 2011-12-31 | CN¥17.91 Million ≈ $2.62 Million |
-44.60% |
| 2010-12-31 | CN¥32.34 Million ≈ $4.73 Million |
-8.23% |
| 2009-12-31 | CN¥35.24 Million ≈ $5.16 Million |
+28.58% |
| 2008-12-31 | CN¥27.41 Million ≈ $4.01 Million |
+136.25% |
| 2007-12-31 | CN¥11.60 Million ≈ $1.70 Million |
-- |
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. It offers injectable mouse nerve growth factor, human interferon, vaccines, traditional Chinese medicine decoction pieces, and pharmaceutical distribution. The company was founded in 1998 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Y… Read more